Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry.

Armitage JD, Tan DBA, Cha L, Clark M, Gray ES, Fuller KA, Moodley YP.

J Immunol Methods. 2019 May;468:61-66. doi: 10.1016/j.jim.2019.03.006. Epub 2019 Mar 16.

PMID:
30885719
2.

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.

Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, Khattak MA, Frank MH, Millward M, Ziman M.

Cancers (Basel). 2019 Jan 30;11(2). pii: E157. doi: 10.3390/cancers11020157.

3.

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A, Cebon J, Sandhu S, McArthur GA, Millward M, Ziman M, Dobrovic A, Wong SQ.

J Mol Diagn. 2019 May;21(3):418-426. doi: 10.1016/j.jmoldx.2018.12.001. Epub 2019 Feb 5.

PMID:
30731208
4.

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.

McEvoy AC, Pereira MR, Reid A, Pearce R, Cowell L, Al-Ogaili Z, Khattak MA, Millward M, Meniawy TM, Gray ES, Ziman M.

Oncotarget. 2019 Jan 4;10(2):113-122. doi: 10.18632/oncotarget.26451. eCollection 2019 Jan 4.

5.

Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.

Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, McEvoy AC, Warburton L, Hayward NK, Khattak MA, Meniawy TM, Millward M, Amanuel B, Ziman M, Gray ES.

Mol Oncol. 2019 Feb;13(2):171-184. doi: 10.1002/1878-0261.12391. Epub 2018 Dec 7.

6.

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, Khattak MA, Meniawy TM, Millward M, Ziman M, Gray ES.

BMC Cancer. 2018 Jul 9;18(1):726. doi: 10.1186/s12885-018-4637-6.

7.

Probing Zika Virus Neutralization Determinants with Glycoprotein Mutants Bearing Linear Epitope Insertions.

Chambers MT, Schwarz MC, Sourisseau M, Gray ES, Evans MJ.

J Virol. 2018 Aug 29;92(18). pii: e00505-18. doi: 10.1128/JVI.00505-18. Print 2018 Sep 15.

8.

Melanoma circulating tumor cells: Benefits and challenges required for clinical application.

Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M.

Cancer Lett. 2018 Jun 28;424:1-8. doi: 10.1016/j.canlet.2018.03.013. Epub 2018 Mar 14. Review.

9.

Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.

McEvoy AC, Wood BA, Ardakani NM, Pereira MR, Pearce R, Cowell L, Robinson C, Grieu-Iacopetta F, Spicer AJ, Amanuel B, Ziman M, Gray ES.

J Mol Diagn. 2018 Mar;20(2):240-252. doi: 10.1016/j.jmoldx.2017.11.009. Epub 2018 Jan 2.

PMID:
29305225
10.

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.

McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel B, Millward M, Ziman M, Gray ES.

Oncotarget. 2017 Aug 18;8(45):78890-78900. doi: 10.18632/oncotarget.20354. eCollection 2017 Oct 3.

11.

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device.

Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M.

Oncotarget. 2017 Jun 27;8(40):67355-67368. doi: 10.18632/oncotarget.18641. eCollection 2017 Sep 15.

12.

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.

Calapre L, Warburton L, Millward M, Ziman M, Gray ES.

Cancer Lett. 2017 Sep 28;404:62-69. doi: 10.1016/j.canlet.2017.06.030. Epub 2017 Jul 4. Review.

13.

SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes.

Calapre L, Gray ES, Kurdykowski S, David A, Descargues P, Ziman M.

BMC Dermatol. 2017 Jun 10;17(1):8. doi: 10.1186/s12895-017-0060-y.

14.

Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA Clone.

Schwarz MC, Sourisseau M, Espino MM, Gray ES, Chambers MT, Tortorella D, Evans MJ.

mSphere. 2016 Sep 28;1(5). pii: e00246-16. eCollection 2016 Sep-Oct.

15.

UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance.

Mufhandu HT, Alexandre KB, Gray ES, Morris L, Khati M.

Biochem Biophys Rep. 2016 Jul 12;7:408-414. doi: 10.1016/j.bbrep.2016.07.005. eCollection 2016 Sep.

16.

Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo.

Calapre L, Gray ES, Kurdykowski S, David A, Hart P, Descargues P, Ziman M.

BMC Dermatol. 2016 May 26;16(1):6. doi: 10.1186/s12895-016-0043-4.

17.

Arterial or Venous: Where Are the Circulating Tumor Cells?

Gray ES.

EBioMedicine. 2015 Sep 16;2(11):1596-7. doi: 10.1016/j.ebiom.2015.09.029. eCollection 2015 Nov. No abstract available.

18.

Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients.

Zaenker P, Gray ES, Ziman MR.

Autoimmun Rev. 2016 May;15(5):477-83. doi: 10.1016/j.autrev.2016.01.017. Epub 2016 Jan 28. Review.

19.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.

20.

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF.

Cell Host Microbe. 2015 Sep 9;18(3):354-62. doi: 10.1016/j.chom.2015.08.006.

21.

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.

Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L.

Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.

22.

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.

Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M.

J Invest Dermatol. 2015 Aug;135(8):2040-2048. doi: 10.1038/jid.2015.127. Epub 2015 Apr 1.

23.

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.

Reid AL, Freeman JB, Millward M, Ziman M, Gray ES.

Clin Biochem. 2015 Oct;48(15):999-1002. doi: 10.1016/j.clinbiochem.2014.12.007. Epub 2014 Dec 16.

PMID:
25523300
24.

Prevalence of malnutrition in children under five and school-age children in Milot Valley, Haiti.

Rollet SR, Gray ES, Previl H, Forrester JE.

Public Health. 2014 Dec;128(12):1094-8. doi: 10.1016/j.puhe.2014.10.002. Epub 2014 Nov 6.

PMID:
25454253
25.

Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.

Bandawe GP, Moore PL, Werner L, Gray ES, Sheward DJ, Madiga M, Nofemela A, Thebus R, Marais JC, Maboko L, Abdool Karim SS, Hoelscher M, Morris L, Williamson C.

J Infect Dis. 2015 May 1;211(9):1461-6. doi: 10.1093/infdis/jiu633. Epub 2014 Nov 14.

26.

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.

Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M.

BMC Cancer. 2014 Jun 11;14:423. doi: 10.1186/1471-2407-14-423.

27.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.

Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium.

Virol J. 2013 Dec 2;10:347. doi: 10.1186/1743-422X-10-347.

28.

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL.

PLoS Pathog. 2013 Oct;9(10):e1003738. doi: 10.1371/journal.ppat.1003738. Epub 2013 Oct 31.

29.

Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Alexandre KB, Moore PL, Nonyane M, Gray ES, Ranchobe N, Chakauya E, McMahon JB, O'Keefe BR, Chikwamba R, Morris L.

Virology. 2013 Nov;446(1-2):66-76. doi: 10.1016/j.virol.2013.07.019. Epub 2013 Aug 15.

30.

Heat stress: a risk factor for skin carcinogenesis.

Calapre L, Gray ES, Ziman M.

Cancer Lett. 2013 Aug 28;337(1):35-40. doi: 10.1016/j.canlet.2013.05.039. Epub 2013 Jun 5. Review.

PMID:
23748013
31.

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.

Klinac D, Gray ES, Millward M, Ziman M.

Front Oncol. 2013 Mar 19;3:54. doi: 10.3389/fonc.2013.00054. eCollection 2013.

32.

Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.

Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L.

J Virol. 2013 May;87(9):4882-94. doi: 10.1128/JVI.03424-12. Epub 2013 Feb 13.

33.

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L.

Nat Med. 2012 Nov;18(11):1688-92. doi: 10.1038/nm.2985. Epub 2012 Oct 21.

34.

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T.

Virology. 2012 Nov 25;433(2):410-20. doi: 10.1016/j.virol.2012.08.033. Epub 2012 Sep 18.

35.

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.

Freeman JB, Gray ES, Millward M, Pearce R, Ziman M.

J Transl Med. 2012 Sep 15;10:192. doi: 10.1186/1479-5876-10-192.

36.

The development of CD4 binding site antibodies during HIV-1 infection.

Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M; CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR.

J Virol. 2012 Jul;86(14):7588-95. doi: 10.1128/JVI.00734-12. Epub 2012 May 9.

37.

UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, Wibmer CK, Moore PL, Morris L, Khati M.

J Virol. 2012 May;86(9):4989-99. doi: 10.1128/JVI.06893-11. Epub 2012 Feb 29.

38.

The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.

Alexandre KB, Gray ES, Mufhandu H, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L.

Virology. 2012 Feb 20;423(2):175-86. doi: 10.1016/j.virol.2011.12.001. Epub 2011 Dec 29.

39.

Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting.

Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool Karim SS, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao HX, Haynes BF.

PLoS One. 2011;6(9):e23532. doi: 10.1371/journal.pone.0023532. Epub 2011 Sep 30.

40.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

41.

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.

Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L.

J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.

42.

Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu JS, Lambson B, Abdool Karim S, Whitesides J, Tomaras GD, Haynes BF, Morris L, Liao HX.

J Virol. 2011 Aug;85(15):7719-29. doi: 10.1128/JVI.00563-11. Epub 2011 May 25.

43.

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team.

J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.

44.

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.

45.

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L.

Virology. 2010 Jun 20;402(1):187-96. doi: 10.1016/j.virol.2010.03.021. Epub 2010 Apr 13.

46.

Specificity of the autologous neutralizing antibody response.

Moore PL, Gray ES, Morris L.

Curr Opin HIV AIDS. 2009 Sep;4(5):358-63. doi: 10.1097/COH.0b013e32832ea7e8. Review.

47.

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L; CAPRISA 002 Study; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.

48.

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L.

J Virol. 2009 Nov;83(21):11265-74. doi: 10.1128/JVI.01359-09. Epub 2009 Aug 19.

49.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

50.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

Supplemental Content

Support Center